US20080226641A1 - Outer surface proteins, their genes, and their use - Google Patents
Outer surface proteins, their genes, and their use Download PDFInfo
- Publication number
- US20080226641A1 US20080226641A1 US11/892,013 US89201307A US2008226641A1 US 20080226641 A1 US20080226641 A1 US 20080226641A1 US 89201307 A US89201307 A US 89201307A US 2008226641 A1 US2008226641 A1 US 2008226641A1
- Authority
- US
- United States
- Prior art keywords
- group
- peptide
- polynucleotide
- gene
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 53
- 108010052285 Membrane Proteins Proteins 0.000 title description 2
- 102000018697 Membrane Proteins Human genes 0.000 title description 2
- 241000193990 Streptococcus sp. 'group B' Species 0.000 claims abstract description 29
- 239000012634 fragment Substances 0.000 claims abstract description 27
- 229960005486 vaccine Drugs 0.000 claims abstract description 15
- 208000015181 infectious disease Diseases 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 15
- 108091033319 polynucleotide Proteins 0.000 claims description 14
- 102000040430 polynucleotide Human genes 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 208000019206 urinary tract infection Diseases 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 2
- 230000001018 virulence Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 108010056007 Glyceraldehyde-3-Phosphate Dehydrogenase (NADP+)(Phosphorylating) Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010061372 Streptococcal infection Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 238000002649 immunization Methods 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 6
- 230000003053 immunization Effects 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000013615 primer Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 3
- 108010035824 Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+) Proteins 0.000 description 3
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- BGWGXPAPYGQALX-ARQDHWQXSA-N beta-D-fructofuranose 6-phosphate Chemical compound OC[C@@]1(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BGWGXPAPYGQALX-ARQDHWQXSA-N 0.000 description 3
- 230000034659 glycolysis Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 206010053555 Arthritis bacterial Diseases 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 208000035357 Focal Infection Diseases 0.000 description 2
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 2
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 2
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 208000004575 Infectious Arthritis Diseases 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 2
- 206010061308 Neonatal infection Diseases 0.000 description 2
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 2
- 108010053775 Nisin Proteins 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 2
- 101710113020 Ornithine transcarbamylase, mitochondrial Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 241000194019 Streptococcus mutans Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000007244 Zea mays Nutrition 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 235000013477 citrulline Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 239000004309 nisin Substances 0.000 description 2
- 235000010297 nisin Nutrition 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 201000001223 septic arthritis Diseases 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- LJQLQCAXBUHEAZ-UWTATZPHSA-N 3-phospho-D-glyceroyl dihydrogen phosphate Chemical compound OP(=O)(O)OC[C@@H](O)C(=O)OP(O)(O)=O LJQLQCAXBUHEAZ-UWTATZPHSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 101150017606 GPI gene Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000204051 Mycoplasma genitalium Species 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 241000588651 Neisseria flavescens Species 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241001464947 Streptococcus milleri Species 0.000 description 1
- 241000194021 Streptococcus suis Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000192593 Synechocystis sp. PCC 6803 Species 0.000 description 1
- 241000204652 Thermotoga Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 108010006886 Vitrogen Proteins 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- FFQKYPRQEYGKAF-UHFFFAOYSA-N carbamoyl phosphate Chemical compound NC(=O)OP(O)(O)=O FFQKYPRQEYGKAF-UHFFFAOYSA-N 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 108010009719 mutanolysin Proteins 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- PJTTXANTBQDXME-UGDNZRGBSA-N sucrose 6(F)-phosphate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 PJTTXANTBQDXME-UGDNZRGBSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1018—Carboxy- and carbamoyl transferases (2.1.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1217—Phosphotransferases with a carboxyl group as acceptor (2.7.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
- C12N9/92—Glucose isomerase (5.3.1.5; 5.3.1.9; 5.3.1.18)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- This invention relates to the identification of outer surface proteins, their genes, and their use. More particularly, it relates to their use in therapy, for immunisation and in screening for drugs.
- GBS Group B Streptococcus
- Streptococcus aralactiae is the causative agent of various conditions.
- GBS causes:
- This infection usually begins in utero and causes severe septicaemia and pneumonia in infants, which is lethal if untreated and even with treatment is associated with a 10-20% mortality rate.
- This infection occurs in the period shortly after birth until about 3 months of age. It causes a septicaemia, which is complicated by meningitis in 90% of cases. Other focal infections also occur including osteomyelitis, septic arthritis, abscesses and endopthalmitis.
- GBS is a cause of urinary tract infections and in pregnancy accounts for about 10% of all infections. Veterinary infections.
- GBS causes chronic mastitis in cows. This, in turn, leads to reduced milk production and is therefore of considerable economic importance.
- GBS infections can be treated with antibiotics.
- immunisation is preferable. It is therefore desirable to develop an immunogen that could be used in a therapeutically-effective vaccine.
- the present invention is based on the identification of a series of genes in GBS, and also related organisms, the products of which may be associated with the outer surface of the organism and may therefore be useful as targets for immunotherapy.
- a peptide is encoded by an operon including any of the genes identified herein as MS4, MS10, MS11, MS14 and MS16, obtainable from Group B Streptococcus, or a homologue or functional fragment thereof.
- Such a peptide is suitable for therapeutic use, e.g. when isolated.
- a functional fragment of the peptide is used herein to define a part of the gene or peptide which retains the activity of the whole gene or peptide.
- a functional fragment of the peptide may be used as an antigenic determinant, useful in a vaccine or in the production of antibodies.
- a gene fragment may be used to encode the active peptide.
- the gene fragment may have utility in gene therapy, targeting the wild-type gene in vivo to exert a therapeutic effect.
- a peptide according to the present invention may comprise any of the amino acid sequences identified herein as SEQ ID NOS. 2, 4, 6, 8, 10 and 12, or a functional fragment thereof.
- peptides of the present invention may be suitable candidates for the production of therapeutically-effective vaccines against GBS.
- therapeutically-effective is intended to include the prophylactic effect of vaccines.
- a vaccine may comprise a peptide according to the invention, or the means for its expression, for the treatment of infection.
- This vaccine may be administered to females either prior to or during pregnancy to protect mother and neonate against infection by GBS.
- the peptides or genes may be used for screening potential antimicrobial drugs or for the detection of virulence.
- a further aspect of this invention is the use of any of the products identified herein, for the treatment or prevention of a condition associated with infection by a Group B Streptococcal strain.
- the protein has been described for use in the treatment of patients, veterinary uses of the products of the invention are also considered to be within the scope of the present invention.
- the peptides or the vaccines may be used in the treatment of chronic mastitis, especially in cows.
- the present invention is described with reference to Group B Streptococcal strain M732.
- GBS strains and many other bacterial strains are likely to include related peptides or proteins having amino acid sequence homology with the peptide of M732.
- Organisms likely to contain the peptides include, but are not limited to, S. pneumoniae, S. pycgenes, S. suis, S. milleri , Group C and Group G Streptococci and Enterococci. Vaccines to each of these may be developed in the same way as described for GBS.
- the peptides that may be useful for the production of vaccines have greater than 40% sequence similarity with the peptides identified herein. More preferably, the peptides have greater than 60% sequence similarity. Most preferably, the peptides have greater than 80% sequence similarity, e.g. 95% similarity.
- sequence homologies may be established by searching in existing databases, e.g. EMBL or Genbank.
- Peptides or proteins according to the invention may be purified and isolated by methods known in the art. In particular, having identified the gene sequence, it will be possible to use recombinant techniques to express the genes in a suitable host. Active fragments and homologues can be identified and may be useful in therapy. For example, the peptides or their active fragments may be used as antigenic determinants in a vaccine, to elicit an immune response. They may also be used in the preparation of antibodies, for passive immunisation, or diagnostic applications. Suitable antibodies include monoclonal antibodies, or fragments thereof, including single chain fv fragments. Methods for the preparation of antibodies will be apparent to those skilled in the art.
- Vaccine compositions can be formulated with suitable carriers or adjuvants, e.g. alum, as necessary or desired, and used in therapy, to provide effective immunisation against Group B Streptococci or other related microorganisms.
- suitable carriers or adjuvants e.g. alum, as necessary or desired, and used in therapy, to provide effective immunisation against Group B Streptococci or other related microorganisms.
- suitable carriers or adjuvants e.g. alum
- a suitable amount of an active component of the invention can be selected, for therapeutic use, as can suitable carriers or excipients, and routes of administration. These factors will be chosen or determined according to known criteria such as the nature/severity of the condition to be treated, the type or health of the subject etc.
- Todd-Hewitt broth was inoculated with GBS and allowed to grow overnight at 37° C.
- the cells were harvested by centrifugation and washed with Phosphate Buffered Saline (PBS).
- PBS Phosphate Buffered Saline
- the cells were resuspended in an osmotic buffer (20% (w/v) Sucrose, 20 mM Tris-HCl pH 7.0, 10 mM MgCl 2 ) containing protease inhibitors (1 mM PMSF, 10 mM Iodoeacetic Acid, 10 mM 1,10-Phenanthroline, 1 ⁇ M Pepstatin A) and Mutanolysin at a final concentration of 4 Units per microlitre. This was incubated (shaking) at 37° C. for 2 hours.
- the sample was dialysed against ultra high quality water and lyophilised. After resuspension in loading buffer, the proteins were separated by preparative 2-Dimensional-Gel Electrophoresis. Following electrophoresis an individual spot was chosen for study. The spot was subjected to in-gel tryptic digestion. The resulting peptides were extracted from the gel and purified using microbore RP-HPLC. Fractions were collected every 45 seconds and a portion of these consistent with the regions of UV absorbance were analysed by Delayed Extraction-Matrix Assisted Laser Desorption-Time of Flight Mass Spectrometry (DE-MALDI-TOF-MS). Peptides not observed in a blank preparation were then subjected to sequencing using Nanospray-MS/MS
- oligonucleotides were designed to be used in a polymerase chain reaction (PCR) to amplify the DNA segment lying between the peptide sequences identified.
- PCR polymerase chain reaction
- PCR amplification resulted in the production of several polynucleotide fragments, each of which was cloned into the pCR 2.1-TOPO vector (Invitrogen BV, Netherlands) according to manufacturers protocol.
- the DNA fragment in each plasmid was identified by sequencing and then used to obtain the full-length gene sequence, as follows.
- oligonucleotide primers were designed for genomic DNA sequencing. These primers were designed so as to sequence in an outward direction from the obtained sequence. Once read, the sequence obtained was checked to see if the 5′ and 3′ termini of the gene had been reached. The presence of these features was identified by checking against homologous sequences, and for the 5′ end the presence of an AUG start codon (or accepted alternative) preceded by a Shine-Dalgarno consensus sequence, and for the 3′ end, the presence of a translation termination (Stop) codon.
- AUG start codon or accepted alternative
- primers were designed for amplification of full-length product from GBS genomic DNA. Primers used included restriction enzyme recognition sites (NcoI at the 5′ end and EcoO109I at the 3′ end) to allow subsequent cloning of the product into the Lactococcal expression system used.
- PCR was carried out using the primers, and the products cloned into a pCR 2.1 cloning vector (In Vitrogen). Following confirmation of the presence of the cloned fragment, the DNA was excised using the restriction enzymes NcoI and EcoO109I.
- the vector into which this fragment was inserted was a modified version of pNZ8048 (Kuipers, O. P. et al. (1998) J. Biotech 64: 15-21).
- This vector harbouring a lactococcal origin of replication, a chloramphenicol resistance marker, an inducible nisin promoter and a multicloning site was altered by the replacement of the multicloning site with two 10 ⁇ His tags, flanked on the 5-most end with an NcoI site, split in the middle with a multicloning site (including an EcoO109I site), and a Stop (termination) codon at the 3′ end of the His tags.
- the gene of interest was inserted so that a 10 ⁇ His tag was in the 3′ position relative to the coding region.
- L. lactis strain NZ9000-Kuipers, O. P. et al. (1998) supra
- a 400 ml liquid culture was set up and translation of the protein was induced by the addition of nisin to the culture.
- the cells were harvested and lysed by bead beating.
- the resultant lysate was cleared by centrifugation, then passed over a metal affinity (Talon, Clonetech) column. The column was washed repeatedly before bound proteins were eluted with Imidazole.
- the recombinant protein obtained was then used to immunise New Zealand white rabbits, with pre-immune sera being harvested prior to immunisation. Following a boost, the rabbits were sacrificed and sera collected. This sera was used in Western blots, ELISA and animal protection models.
- Group B Streptococcus was grown in 20 ml Todd Hewitt broth (THB) for 8 hours, harvested and resuspended in 5 ml PBS. 50 ⁇ l aliquots of this were used to coat wells in a 96 well plate (Nunc Immuno-Sorb). This was left at 4° C. overnight to allow for absorbance of the bacteria onto the plate. Plates were washed twice with PBS, then blocked with 3% BSA in PBS for 1 hr at 37° C. Plates were again washed. Serial 10 fold dilutions of the sera were made in PBS and 50 ⁇ l of these dilutions were added to the wells of the plate, in duplicate.
- the plate was covered and incubated for 1 hr at 37° C. The plate was washed, then. 501 anti-rabbit alkaline phosphatase conjugated secondary antibody at a concentration of 1:5000 was added to each well. Following incubation at 37° C. for an hour, the plate was washed again. 50 ⁇ l substrate (PNPP) was added to each well, and the reaction allowed to proceed for 30 min before the absorbance was read at 405 nm.
- PNPP 50 ⁇ l substrate
- GBS M732 was grown up in THB until mid-log phase was reached—approximately 5 hours. Cells were counted in a counting chamber, and bacteria were diluted to give a concentration of 2 ⁇ 10 7 bacteria per ml in pre-immune or test sera. 50 ⁇ l of this was injected via the intraperitoneal route into 0-1 day old mice. The mice were observed for survival over 48 hours.
- a first plasmid was termed MS4.
- the cloned DNA fragment was sequenced and the nucleotide and deduced amino acid sequence (SEQ ID NO. 1 and 2) was used to search protein databases.
- Homologues to the GBS MS4 gene product can be identified in Clostridium perfingens, Haemophilus influenzae, Neisseria flavescens and Thermatoga maritima .
- the homologues are the genes for Ornithine Carbamoyltransferase (OCT).
- OCT Ornithine Carbamoyltransferase
- this enzyme catalyses the second step in the Urea cycle, the conversion of ornithine to citrulline, a reaction requiring carbomyl phosphate.
- ODC is one of the three enzymes involved in Arginine Deaminase activity—a system which protects bacteria from acid damage.
- ODC is responsible for the conversion of citrulline to ornithine and carbamoyl phosphate (the opposite role to that in eukaryotes) (Casiano-Colon, A and Marquis, R. E. 1988. Appl. Environ. Microbiol. 54: 1318-1324, Cunin, R. et al. 1986. Microbiol. Rev. 50: 314-352).
- MS11 A second plasmid was termed MS11.
- the nucleotide and deduced amino acid sequence (SEQ ID NOS. 3 and 4) were used to search protein databases.
- GBS MS11 Homologues to the GBS MS11 gene product can be identified in Lactobacillus delbrueckii, Thermotoga maritina, Clostridium acetobulylicum, Bacillus megaterium, Triticum aestivium and Synechocystis PCC6803.
- the homologues are the genes for the protein Phosphoglycerate Kinase (PGK).
- PGK is a major enzyme in the glycolytic pathway, being involved in the conversion of Glyceraldehyde-3-phosphate to Phosphoenolpyruvate. In particular, it is involved in the catalysis of the reaction between Glycerate-1,3-diphosphate and 3-Phospho-Glycerate, releasing a phosphate in the forward reaction.
- a third plasmid was termed pMS16.
- the 5′ and 3′ cloned DNA fragments were sequenced and the nucleotide and deduced amino acid sequences for each are shown as SEQ ID NOS. 5 and 6 for the 5′ fragment and SEQ ID NOS. 7 and 8 for the 3′ fragment.
- Homologues to the GBS MS16 gene product can be identified in Bacillus stearothermophilus, Bacillus subtilis and Mycoplasma genitalium.
- homologues are the genes for the protein Glucose-6-Phosphate Isomerase (GPI).
- Glucose-6-Phospate Isomerase catalyses the reaction between Glucose-6-phosphate and Fructose-6-Phosphate in both glycolysis (G6P to F6P) and gluconeogenesis (F6P to G6P). Mutations in the gpi gene have been shown to confer purine analogue sensitivity to organisms.
- a fourth plasmid was termed pMS14.
- the cloned DNA fragment was sequenced and the nucleotide and deduced amino acid sequence (SEQ ID NOS. 9 and 10) was used to search protein databases.
- Homologues to the GBS MS14 gene product can be identified in Bacillus subtilis, Bacillus stearothermophilus, Mus musculus, Bos taurus and Zea mays .
- the homologues are the genes for the protein Purine Nucleoside Phosphatase (PNP).
- PNP Purine Nucleoside Phosphatase
- the function of this enzyme is to cleave the nucleosides guanosine or inosine to their respective basis and sugar-1-phosphate molecules in the presence of orthophosphate.
- a fifth plasmid was termed pMS10.
- the cloned DNA fragment was sequenced.
- the nucleotide and deduced amino acid sequence (SEQ ID NOS. 11 and 12) was used to search protein databases.
- NPGAP-3-DH Nonphosphorylating, NADP-Dependent Glyceraldehyde-3-Phosphate Dehydrogenase
Abstract
Description
- This invention relates to the identification of outer surface proteins, their genes, and their use. More particularly, it relates to their use in therapy, for immunisation and in screening for drugs.
- Group B Streptococcus (GBS), also known as Streptococcus aralactiae, is the causative agent of various conditions. In particular, GBS causes:
- This infection usually begins in utero and causes severe septicaemia and pneumonia in infants, which is lethal if untreated and even with treatment is associated with a 10-20% mortality rate.
- This infection occurs in the period shortly after birth until about 3 months of age. It causes a septicaemia, which is complicated by meningitis in 90% of cases. Other focal infections also occur including osteomyelitis, septic arthritis, abscesses and endopthalmitis.
- These appear to be increasingly common and occur most frequently in women who have just delivered a baby, the elderly and the immunocompromised. They are characterised by septicaemia and focal infections including osteomyelitis, septic arthritis, abscesses and endopthalmitis.
- GBS is a cause of urinary tract infections and in pregnancy accounts for about 10% of all infections. Veterinary infections.
- GBS causes chronic mastitis in cows. This, in turn, leads to reduced milk production and is therefore of considerable economic importance.
- GBS infections can be treated with antibiotics. However, immunisation is preferable. It is therefore desirable to develop an immunogen that could be used in a therapeutically-effective vaccine.
- The present invention is based on the identification of a series of genes in GBS, and also related organisms, the products of which may be associated with the outer surface of the organism and may therefore be useful as targets for immunotherapy.
- According to one aspect of the invention, a peptide is encoded by an operon including any of the genes identified herein as MS4, MS10, MS11, MS14 and MS16, obtainable from Group B Streptococcus, or a homologue or functional fragment thereof. Such a peptide is suitable for therapeutic use, e.g. when isolated.
- The term “functional fragments” is used herein to define a part of the gene or peptide which retains the activity of the whole gene or peptide. For example, a functional fragment of the peptide may be used as an antigenic determinant, useful in a vaccine or in the production of antibodies.
- A gene fragment may be used to encode the active peptide. Alternatively, the gene fragment may have utility in gene therapy, targeting the wild-type gene in vivo to exert a therapeutic effect.
- A peptide according to the present invention may comprise any of the amino acid sequences identified herein as SEQ ID NOS. 2, 4, 6, 8, 10 and 12, or a functional fragment thereof.
- Because of the extracellular or cell surface location, the peptides of the present invention may be suitable candidates for the production of therapeutically-effective vaccines against GBS. The term “therapeutically-effective” is intended to include the prophylactic effect of vaccines. For example, a vaccine may comprise a peptide according to the invention, or the means for its expression, for the treatment of infection.
- This vaccine may be administered to females either prior to or during pregnancy to protect mother and neonate against infection by GBS.
- According to another aspect of the invention, the peptides or genes may be used for screening potential antimicrobial drugs or for the detection of virulence.
- A further aspect of this invention is the use of any of the products identified herein, for the treatment or prevention of a condition associated with infection by a Group B Streptococcal strain.
- Although the protein has been described for use in the treatment of patients, veterinary uses of the products of the invention are also considered to be within the scope of the present invention. In particular, the peptides or the vaccines may be used in the treatment of chronic mastitis, especially in cows.
- The present invention is described with reference to Group B Streptococcal strain M732. However, all the GBS strains and many other bacterial strains are likely to include related peptides or proteins having amino acid sequence homology with the peptide of M732. Organisms likely to contain the peptides include, but are not limited to, S. pneumoniae, S. pycgenes, S. suis, S. milleri, Group C and Group G Streptococci and Enterococci. Vaccines to each of these may be developed in the same way as described for GBS.
- Preferably, the peptides that may be useful for the production of vaccines have greater than 40% sequence similarity with the peptides identified herein. More preferably, the peptides have greater than 60% sequence similarity. Most preferably, the peptides have greater than 80% sequence similarity, e.g. 95% similarity.
- Having characterised a gene according to the invention, it is possible to use the gene sequence to establish homologies in other microorganisms. In this way it is possible to determine whether other microorganisms have similar outer surface products. Sequence homologies may be established by searching in existing databases, e.g. EMBL or Genbank.
- Peptides or proteins according to the invention may be purified and isolated by methods known in the art. In particular, having identified the gene sequence, it will be possible to use recombinant techniques to express the genes in a suitable host. Active fragments and homologues can be identified and may be useful in therapy. For example, the peptides or their active fragments may be used as antigenic determinants in a vaccine, to elicit an immune response. They may also be used in the preparation of antibodies, for passive immunisation, or diagnostic applications. Suitable antibodies include monoclonal antibodies, or fragments thereof, including single chain fv fragments. Methods for the preparation of antibodies will be apparent to those skilled in the art.
- The preparation of vaccines based on attenuated microorganisms is known to those skilled in the art. Vaccine compositions can be formulated with suitable carriers or adjuvants, e.g. alum, as necessary or desired, and used in therapy, to provide effective immunisation against Group B Streptococci or other related microorganisms. The preparation of vaccine formulations will be apparent to the skilled person.
- More generally, and as is well known to those skilled in the art, a suitable amount of an active component of the invention can be selected, for therapeutic use, as can suitable carriers or excipients, and routes of administration. These factors will be chosen or determined according to known criteria such as the nature/severity of the condition to be treated, the type or health of the subject etc.
- The products of the present invention were identified as follows:
- Todd-Hewitt broth was inoculated with GBS and allowed to grow overnight at 37° C. The cells were harvested by centrifugation and washed with Phosphate Buffered Saline (PBS). The cells were resuspended in an osmotic buffer (20% (w/v) Sucrose, 20 mM Tris-HCl pH 7.0, 10 mM MgCl2) containing protease inhibitors (1 mM PMSF, 10 mM Iodoeacetic Acid, 10 mM 1,10-Phenanthroline, 1 μM Pepstatin A) and Mutanolysin at a final concentration of 4 Units per microlitre. This was incubated (shaking) at 37° C. for 2 hours.
- Cells and debris were removed first by high speed centrifugation, then ultra-centrifugation for 1 hour. The resultant supernatant containing cell wall proteins was concentrated under pressure using an ultrafiltration device (10,000 molecular weight cut-off).
- The sample was dialysed against ultra high quality water and lyophilised. After resuspension in loading buffer, the proteins were separated by preparative 2-Dimensional-Gel Electrophoresis. Following electrophoresis an individual spot was chosen for study. The spot was subjected to in-gel tryptic digestion. The resulting peptides were extracted from the gel and purified using microbore RP-HPLC. Fractions were collected every 45 seconds and a portion of these consistent with the regions of UV absorbance were analysed by Delayed Extraction-Matrix Assisted Laser Desorption-Time of Flight Mass Spectrometry (DE-MALDI-TOF-MS). Peptides not observed in a blank preparation were then subjected to sequencing using Nanospray-MS/MS
- Using this peptide sequence information, degenerate oligonucleotides were designed to be used in a polymerase chain reaction (PCR) to amplify the DNA segment lying between the peptide sequences identified.
- PCR amplification resulted in the production of several polynucleotide fragments, each of which was cloned into the pCR 2.1-TOPO vector (Invitrogen BV, Netherlands) according to manufacturers protocol.
- The DNA fragment in each plasmid was identified by sequencing and then used to obtain the full-length gene sequence, as follows.
- Using the identified DNA fragment, oligonucleotide primers were designed for genomic DNA sequencing. These primers were designed so as to sequence in an outward direction from the obtained sequence. Once read, the sequence obtained was checked to see if the 5′ and 3′ termini of the gene had been reached. The presence of these features was identified by checking against homologous sequences, and for the 5′ end the presence of an AUG start codon (or accepted alternative) preceded by a Shine-Dalgarno consensus sequence, and for the 3′ end, the presence of a translation termination (Stop) codon.
- Upon identification of the full-length gene, primers were designed for amplification of full-length product from GBS genomic DNA. Primers used included restriction enzyme recognition sites (NcoI at the 5′ end and EcoO109I at the 3′ end) to allow subsequent cloning of the product into the Lactococcal expression system used.
- PCR was carried out using the primers, and the products cloned into a pCR 2.1 cloning vector (In Vitrogen). Following confirmation of the presence of the cloned fragment, the DNA was excised using the restriction enzymes NcoI and EcoO109I.
- The vector into which this fragment was inserted was a modified version of pNZ8048 (Kuipers, O. P. et al. (1998) J. Biotech 64: 15-21). This vector, harbouring a lactococcal origin of replication, a chloramphenicol resistance marker, an inducible nisin promoter and a multicloning site was altered by the replacement of the multicloning site with two 10×His tags, flanked on the 5-most end with an NcoI site, split in the middle with a multicloning site (including an EcoO109I site), and a Stop (termination) codon at the 3′ end of the His tags.
- The gene of interest was inserted so that a 10× His tag was in the 3′ position relative to the coding region. Following transformation of the recombinant plasmid into L. lactis (strain NZ9000-Kuipers, O. P. et al. (1998) supra), a 400 ml liquid culture was set up and translation of the protein was induced by the addition of nisin to the culture. After a 2 hour incubation, the cells were harvested and lysed by bead beating. The resultant lysate was cleared by centrifugation, then passed over a metal affinity (Talon, Clonetech) column. The column was washed repeatedly before bound proteins were eluted with Imidazole.
- To identify fractions containing the His-tagged recombinant protein, an aliquot from each fraction was analysed by SDS-PAGE, Western blotted and probed with anti-His antibodies.
- The recombinant protein obtained was then used to immunise New Zealand white rabbits, with pre-immune sera being harvested prior to immunisation. Following a boost, the rabbits were sacrificed and sera collected. This sera was used in Western blots, ELISA and animal protection models.
- Using the sera obtained from the animal studies, immunosorption studies were carried out.
- Group B Streptococcus was grown in 20 ml Todd Hewitt broth (THB) for 8 hours, harvested and resuspended in 5 ml PBS. 50 μl aliquots of this were used to coat wells in a 96 well plate (Nunc Immuno-Sorb). This was left at 4° C. overnight to allow for absorbance of the bacteria onto the plate. Plates were washed twice with PBS, then blocked with 3% BSA in PBS for 1 hr at 37° C. Plates were again washed. Serial 10 fold dilutions of the sera were made in PBS and 50 μl of these dilutions were added to the wells of the plate, in duplicate. The plate was covered and incubated for 1 hr at 37° C. The plate was washed, then. 501 anti-rabbit alkaline phosphatase conjugated secondary antibody at a concentration of 1:5000 was added to each well. Following incubation at 37° C. for an hour, the plate was washed again. 50 μl substrate (PNPP) was added to each well, and the reaction allowed to proceed for 30 min before the absorbance was read at 405 nm.
- Animal protection studies were also carried out to test the effectiveness of protection on the immunized rabbits.
- GBS M732 was grown up in THB until mid-log phase was reached—approximately 5 hours. Cells were counted in a counting chamber, and bacteria were diluted to give a concentration of 2×107 bacteria per ml in pre-immune or test sera. 50 μl of this was injected via the intraperitoneal route into 0-1 day old mice. The mice were observed for survival over 48 hours.
- The following Examples illustrate the invention.
- A first plasmid was termed MS4. The cloned DNA fragment was sequenced and the nucleotide and deduced amino acid sequence (SEQ ID NO. 1 and 2) was used to search protein databases.
- Homologues to the GBS MS4 gene product can be identified in Clostridium perfingens, Haemophilus influenzae, Neisseria flavescens and Thermatoga maritima. In all cases the homologues are the genes for Ornithine Carbamoyltransferase (OCT). In eukaryotic systems this enzyme catalyses the second step in the Urea cycle, the conversion of ornithine to citrulline, a reaction requiring carbomyl phosphate. In prokaryotes, ODC is one of the three enzymes involved in Arginine Deaminase activity—a system which protects bacteria from acid damage. In particular, ODC is responsible for the conversion of citrulline to ornithine and carbamoyl phosphate (the opposite role to that in eukaryotes) (Casiano-Colon, A and Marquis, R. E. 1988. Appl. Environ. Microbiol. 54: 1318-1324, Cunin, R. et al. 1986. Microbiol. Rev. 50: 314-352).
- Animal protection studies were carried out as described above. The results are as follows:
-
# pups surviving at time (hrs) Treatment # pups 24 48 PBS 15 6 0 Pre-Immune 41 18 1 Test 41 33 14 - A second plasmid was termed MS11. The nucleotide and deduced amino acid sequence (SEQ ID NOS. 3 and 4) were used to search protein databases.
- Homologues to the GBS MS11 gene product can be identified in Lactobacillus delbrueckii, Thermotoga maritina, Clostridium acetobulylicum, Bacillus megaterium, Triticum aestivium and Synechocystis PCC6803.
- In all cases the homologues are the genes for the protein Phosphoglycerate Kinase (PGK). PGK is a major enzyme in the glycolytic pathway, being involved in the conversion of Glyceraldehyde-3-phosphate to Phosphoenolpyruvate. In particular, it is involved in the catalysis of the reaction between Glycerate-1,3-diphosphate and 3-Phospho-Glycerate, releasing a phosphate in the forward reaction.
- A third plasmid was termed pMS16. The 5′ and 3′ cloned DNA fragments were sequenced and the nucleotide and deduced amino acid sequences for each are shown as SEQ ID NOS. 5 and 6 for the 5′ fragment and SEQ ID NOS. 7 and 8 for the 3′ fragment.
- Homologues to the GBS MS16 gene product can be identified in Bacillus stearothermophilus, Bacillus subtilis and Mycoplasma genitalium.
- In all cases the homologues are the genes for the protein Glucose-6-Phosphate Isomerase (GPI).
- The enzyme Glucose-6-Phospate Isomerase catalyses the reaction between Glucose-6-phosphate and Fructose-6-Phosphate in both glycolysis (G6P to F6P) and gluconeogenesis (F6P to G6P). Mutations in the gpi gene have been shown to confer purine analogue sensitivity to organisms.
- A fourth plasmid was termed pMS14. The cloned DNA fragment was sequenced and the nucleotide and deduced amino acid sequence (SEQ ID NOS. 9 and 10) was used to search protein databases.
- Homologues to the GBS MS14 gene product can be identified in Bacillus subtilis, Bacillus stearothermophilus, Mus musculus, Bos taurus and Zea mays. In all cases the homologues are the genes for the protein Purine Nucleoside Phosphatase (PNP). The function of this enzyme is to cleave the nucleosides guanosine or inosine to their respective basis and sugar-1-phosphate molecules in the presence of orthophosphate.
- A fifth plasmid was termed pMS10. The cloned DNA fragment was sequenced. The nucleotide and deduced amino acid sequence (SEQ ID NOS. 11 and 12) was used to search protein databases.
- Homologues to the GBS MS10 gene product can be identified in Streptococcus mutans, Nicotiana plumb, Pisum sativum and, Zea mays. In all cases the homologues are the genes for the protein Nonphosphorylating, NADP-Dependent Glyceraldehyde-3-Phosphate Dehydrogenase (NPGAP-3-DH). NPGAP-3-DH has been reported as being an important means of generating NADPH for biosynthetic reactions in S. mutans (as opposed to NAD-specific GAP-3-DH which satisfies the requirements of the glycolytic pathway) (Boyd, D. A., Cvitkovitch, D. G. and Hamilton, I. R 1995 J. Bacteriol. 177: 2622-2727).
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/892,013 US20080226641A1 (en) | 1998-12-22 | 2007-08-17 | Outer surface proteins, their genes, and their use |
Applications Claiming Priority (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9828346.8 | 1998-12-22 | ||
GBGB9828346.8A GB9828346D0 (en) | 1998-12-22 | 1998-12-22 | Protein and compositions containing it |
GBGB9901234.6 | 1999-01-20 | ||
GBGB9901234.6A GB9901234D0 (en) | 1999-01-20 | 1999-01-20 | Protein and compositions containing it |
GBGB9901233.8A GB9901233D0 (en) | 1999-01-20 | 1999-01-20 | Protein and compositions containing it |
GBGB9901233.8 | 1999-01-20 | ||
GBGB9908321.4 | 1999-04-12 | ||
GBGB9908321.4A GB9908321D0 (en) | 1999-04-12 | 1999-04-12 | Purine nucleoside phosphatase and compositions containing it |
GBGB9912036.2 | 1999-05-24 | ||
GBGB9912036.2A GB9912036D0 (en) | 1999-05-24 | 1999-05-24 | Glucose-6-phosphate isomerase and compositions containing it |
GBGB9922596.3 | 1999-09-23 | ||
GBGB9922596.3A GB9922596D0 (en) | 1999-09-23 | 1999-09-23 | Protein and compositions containing it |
PCT/GB1999/004376 WO2000037490A2 (en) | 1998-12-22 | 1999-12-22 | Outer surface proteins, their genes, and their use |
US86819501A | 2001-09-14 | 2001-09-14 | |
US11/321,475 US20060104990A1 (en) | 1998-12-22 | 2005-12-29 | Outer surface proteins, their genes, and their use |
US11/892,013 US20080226641A1 (en) | 1998-12-22 | 2007-08-17 | Outer surface proteins, their genes, and their use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/321,475 Division US20060104990A1 (en) | 1998-12-22 | 2005-12-29 | Outer surface proteins, their genes, and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080226641A1 true US20080226641A1 (en) | 2008-09-18 |
Family
ID=27547330
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/868,195 Expired - Fee Related US7217415B1 (en) | 1998-12-22 | 1999-12-22 | NADP-dependent glyceraldehyde-3-phosphate dehydrogenase for therapeutic use |
US11/321,475 Abandoned US20060104990A1 (en) | 1998-12-22 | 2005-12-29 | Outer surface proteins, their genes, and their use |
US11/892,013 Abandoned US20080226641A1 (en) | 1998-12-22 | 2007-08-17 | Outer surface proteins, their genes, and their use |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/868,195 Expired - Fee Related US7217415B1 (en) | 1998-12-22 | 1999-12-22 | NADP-dependent glyceraldehyde-3-phosphate dehydrogenase for therapeutic use |
US11/321,475 Abandoned US20060104990A1 (en) | 1998-12-22 | 2005-12-29 | Outer surface proteins, their genes, and their use |
Country Status (24)
Country | Link |
---|---|
US (3) | US7217415B1 (en) |
EP (2) | EP1140994B1 (en) |
JP (1) | JP2002533065A (en) |
KR (4) | KR100866170B1 (en) |
CN (3) | CN1733800A (en) |
AP (1) | AP2006003504A0 (en) |
AT (1) | ATE297995T1 (en) |
AU (1) | AU758722B2 (en) |
BR (1) | BR9916473A (en) |
CA (1) | CA2354843A1 (en) |
CZ (1) | CZ20012174A3 (en) |
DE (1) | DE69925866T2 (en) |
DK (1) | DK1140994T3 (en) |
EA (1) | EA009885B1 (en) |
ES (1) | ES2241352T3 (en) |
HK (1) | HK1039339A1 (en) |
HU (1) | HUP0201022A3 (en) |
NO (1) | NO20013101L (en) |
NZ (4) | NZ512296A (en) |
OA (1) | OA12425A (en) |
PL (1) | PL351027A1 (en) |
PT (1) | PT1140994E (en) |
SI (1) | SI1140994T1 (en) |
WO (1) | WO2000037490A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6890539B2 (en) * | 1998-12-22 | 2005-05-10 | Microscience, Ltd. | Genes and proteins, and their use |
AP1502A (en) * | 1998-12-22 | 2005-12-20 | Microscience Ltd | Genes and proteins, and their uses. |
JP2002533065A (en) * | 1998-12-22 | 2002-10-08 | マイクロサイエンス リミテッド | Outer surface proteins, their genes, and their uses |
EP2104512A2 (en) * | 2006-12-21 | 2009-09-30 | Emergent Product Development UK Limited | Streptococcus proteins, and their use in vaccination |
CN103060284A (en) * | 2012-10-31 | 2013-04-24 | 内蒙古民族大学 | Streptococcus agalactiae PGK (Phosphoglycerate Kinase) sub-unit recombinant protein and preparation method thereof |
CN110669711A (en) * | 2019-08-09 | 2020-01-10 | 中国水产科学研究院珠江水产研究所 | Recombinant lactococcus lactis and Streptococcus agalactiae vaccine based on pgk gene |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5328996A (en) * | 1989-03-29 | 1994-07-12 | University Of Florida Research Foundation, Inc. | Bacterial plasmin receptors as fibrinolytic agents |
US6015889A (en) * | 1993-03-19 | 2000-01-18 | Gunnar Lindahl | Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition |
US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
US20030104000A1 (en) * | 1998-12-22 | 2003-06-05 | Hughes Martin John Glenton | Genes and proteins, and their use |
US6605709B1 (en) * | 1999-04-09 | 2003-08-12 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Proteus mirabilis for diagnostics and therapeutics |
US6699703B1 (en) * | 1997-07-02 | 2004-03-02 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
US20040044191A1 (en) * | 1997-07-08 | 2004-03-04 | Fischer Carrie L. | 123 human secreted proteins |
US6812021B1 (en) * | 1998-12-22 | 2004-11-02 | Microscience Limited | Genes and proteins and their use |
US20060104990A1 (en) * | 1998-12-22 | 2006-05-18 | Hughes Martin J G | Outer surface proteins, their genes, and their use |
US20070053936A1 (en) * | 1997-08-14 | 2007-03-08 | Doucette-Stamm Lynn A | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0230777B1 (en) * | 1985-12-28 | 1991-04-10 | Ohgen Research Laboratories Ltd., | Antitumor protein gene of streptococcus pyogenes su, plasmids containing the gene, transformant cells harboring the plasmids, and process for producing the antitumor protein |
CA2127550A1 (en) * | 1992-01-08 | 1993-07-22 | Vincent Fischetti | Multifunctional surface protein of streptococci |
IL107458A0 (en) * | 1992-11-02 | 1994-02-27 | Gen Hospital Corp | Conjugate vaccine against group b streptococcus |
ATE240351T1 (en) | 1993-03-19 | 2003-05-15 | Gunnar Lindahl | RIB PROTEIN, A SURFACE PROTEIN WHICH CONFERS IMMUNITY AGAINST MANY GROUP B STREPTOCOCCUS STRAINS, RIB PROTEIN PURIFICATION METHOD, TEST KIT AND PHARMACEUTICAL COMPOSITION (MEDICINE) |
US6346392B1 (en) | 1996-11-27 | 2002-02-12 | Smithkline Beecham Corporation | Polynucleotides encoding a novel glutamine transport ATP-binding protein |
EP1770164B1 (en) * | 1996-10-31 | 2010-09-01 | Human Genome Sciences, Inc. | Streptococcus pneumoniae antigens and vaccines |
US7151171B1 (en) * | 1997-07-02 | 2006-12-19 | sanofi pasteur limited/sanofi pasteur limitée | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
US6165763A (en) * | 1997-10-30 | 2000-12-26 | Smithkline Beecham Corporation | Ornithine carbamoyltransferase |
-
1999
- 1999-12-22 JP JP2000589559A patent/JP2002533065A/en active Pending
- 1999-12-22 ES ES99962421T patent/ES2241352T3/en not_active Expired - Lifetime
- 1999-12-22 NZ NZ512296A patent/NZ512296A/en unknown
- 1999-12-22 PT PT99962421T patent/PT1140994E/en unknown
- 1999-12-22 NZ NZ552871A patent/NZ552871A/en unknown
- 1999-12-22 CN CNA2005100047117A patent/CN1733800A/en active Pending
- 1999-12-22 HU HU0201022A patent/HUP0201022A3/en unknown
- 1999-12-22 PL PL99351027A patent/PL351027A1/en not_active IP Right Cessation
- 1999-12-22 NZ NZ525538A patent/NZ525538A/en unknown
- 1999-12-22 EA EA200100701A patent/EA009885B1/en not_active IP Right Cessation
- 1999-12-22 CN CNA2008101761856A patent/CN101486756A/en active Pending
- 1999-12-22 SI SI9930811T patent/SI1140994T1/en unknown
- 1999-12-22 NZ NZ542777A patent/NZ542777A/en unknown
- 1999-12-22 DK DK99962421T patent/DK1140994T3/en active
- 1999-12-22 CN CN99814781A patent/CN1357045A/en active Pending
- 1999-12-22 EP EP99962421A patent/EP1140994B1/en not_active Expired - Lifetime
- 1999-12-22 US US09/868,195 patent/US7217415B1/en not_active Expired - Fee Related
- 1999-12-22 AP AP2006003504A patent/AP2006003504A0/en unknown
- 1999-12-22 EP EP05009397A patent/EP1574579A3/en not_active Withdrawn
- 1999-12-22 AU AU18779/00A patent/AU758722B2/en not_active Ceased
- 1999-12-22 KR KR1020067017195A patent/KR100866170B1/en not_active IP Right Cessation
- 1999-12-22 CA CA002354843A patent/CA2354843A1/en not_active Abandoned
- 1999-12-22 WO PCT/GB1999/004376 patent/WO2000037490A2/en not_active Application Discontinuation
- 1999-12-22 AT AT99962421T patent/ATE297995T1/en not_active IP Right Cessation
- 1999-12-22 KR KR1020017007910A patent/KR100818815B1/en not_active IP Right Cessation
- 1999-12-22 BR BR9916473-6A patent/BR9916473A/en not_active Application Discontinuation
- 1999-12-22 OA OA1000162A patent/OA12425A/en unknown
- 1999-12-22 DE DE69925866T patent/DE69925866T2/en not_active Expired - Fee Related
- 1999-12-22 CZ CZ20012174A patent/CZ20012174A3/en unknown
-
2001
- 2001-06-21 NO NO20013101A patent/NO20013101L/en not_active Application Discontinuation
- 2001-12-20 HK HK01108929A patent/HK1039339A1/en not_active IP Right Cessation
-
2005
- 2005-12-29 US US11/321,475 patent/US20060104990A1/en not_active Abandoned
-
2007
- 2007-01-26 KR KR1020070008368A patent/KR20070027665A/en not_active Application Discontinuation
- 2007-08-17 US US11/892,013 patent/US20080226641A1/en not_active Abandoned
-
2008
- 2008-05-02 KR KR1020080041439A patent/KR20080052527A/en not_active Application Discontinuation
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5328996A (en) * | 1989-03-29 | 1994-07-12 | University Of Florida Research Foundation, Inc. | Bacterial plasmin receptors as fibrinolytic agents |
US6015889A (en) * | 1993-03-19 | 2000-01-18 | Gunnar Lindahl | Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition |
US6699703B1 (en) * | 1997-07-02 | 2004-03-02 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
US6800744B1 (en) * | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
US7196164B2 (en) * | 1997-07-08 | 2007-03-27 | Human Genome Sciences, Inc. | Secreted protein HHTLF25 |
US20040044191A1 (en) * | 1997-07-08 | 2004-03-04 | Fischer Carrie L. | 123 human secreted proteins |
US20070053936A1 (en) * | 1997-08-14 | 2007-03-08 | Doucette-Stamm Lynn A | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
US20030104000A1 (en) * | 1998-12-22 | 2003-06-05 | Hughes Martin John Glenton | Genes and proteins, and their use |
US6890539B2 (en) * | 1998-12-22 | 2005-05-10 | Microscience, Ltd. | Genes and proteins, and their use |
US20050131210A1 (en) * | 1998-12-22 | 2005-06-16 | Glenton Hughes Martin J. | Genes and proteins, and their use |
US20060104990A1 (en) * | 1998-12-22 | 2006-05-18 | Hughes Martin J G | Outer surface proteins, their genes, and their use |
US6812021B1 (en) * | 1998-12-22 | 2004-11-02 | Microscience Limited | Genes and proteins and their use |
US7217415B1 (en) * | 1998-12-22 | 2007-05-15 | Emergent Product Development Uk Limited | NADP-dependent glyceraldehyde-3-phosphate dehydrogenase for therapeutic use |
US6605709B1 (en) * | 1999-04-09 | 2003-08-12 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Proteus mirabilis for diagnostics and therapeutics |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090274717A1 (en) | Genes and proteins, and their use | |
US20080226641A1 (en) | Outer surface proteins, their genes, and their use | |
US6890539B2 (en) | Genes and proteins, and their use | |
ZA200104819B (en) | Outer surface proteins, their genes, and their use. | |
AU2005203729B2 (en) | Outer surface proteins, their genes, and their use | |
AU2002304016B2 (en) | Outer surface proteins, their genes, and their use | |
NZ533932A (en) | MS11 gene product encoding for a phosphoglycerate kinase, and a purine nucleoside phosphatase and glucose-6-phosphate isomerase proteins from Group B streprococcus and their use in treating bacterial infection | |
WO2002072623A1 (en) | Genes and proteins, and their use | |
PL195869B1 (en) | Outer surface proteins, their genes, and their use | |
ZA200104818B (en) | Genes and proteins, and their use. | |
NZ543923A (en) | Pho3-18 for a theraputic use, particulary in bacterial infection. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: EMERGENT PRODUCT DEVELOPMENT UK LIMITED, UNITED KI Free format text: CHANGE OF NAME;ASSIGNOR:EMERGENT EUROPE LIMITED;REEL/FRAME:021357/0566 Effective date: 20060601 Owner name: MICROSCIENCE LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HUGHES, MARTIN JOHN GLENTON;SANTANGELO, JOSEPH DAVID;LANE, JONATHAN DOUGLAS;AND OTHERS;REEL/FRAME:021357/0299;SIGNING DATES FROM 20010626 TO 20010713 Owner name: EMERGENT EUROPE LIMITED, UNITED KINGDOM Free format text: CHANGE OF NAME;ASSIGNOR:MICROSCIENCE LIMITED;REEL/FRAME:021357/0520 Effective date: 20050722 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |